SRR614900
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.427
- MYOGENESIS+0.420
- HEDGEHOG_SIGNALING+0.343
- SPERMATOGENESIS+0.235
- UV_RESPONSE_DN+0.231
- PANCREAS_BETA_CELLS+0.203
- APICAL_SURFACE+0.199
- ESTROGEN_RESPONSE_EARLY+0.199
- APICAL_JUNCTION+0.157
- ESTROGEN_RESPONSE_LATE+0.126
Top 10 suppressed
- MYC_TARGETS_V1-0.637
- INTERFERON_ALPHA_RESPONSE-0.560
- DNA_REPAIR-0.531
- MYC_TARGETS_V2-0.527
- E2F_TARGETS-0.514
- INTERFERON_GAMMA_RESPONSE-0.504
- UNFOLDED_PROTEIN_RESPONSE-0.477
- G2M_CHECKPOINT-0.475
- IL6_JAK_STAT3_SIGNALING-0.424
- WNT_BETA_CATENIN_SIGNALING-0.376
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418127 | GTEX | — | 0.959 |
| 2 | SRR1471350 | GTEX | — | 0.952 |
| 3 | SRR1375976 | GTEX | — | 0.949 |
| 4 | SRR1431307 | GTEX | — | 0.944 |
| 5 | BS_KPT2WPHW | Ganglioglioma | — | 0.941 |
| 6 | BS_C7N3J4NW | high-grade glioma | — | 0.939 |
| 7 | SRR1314958 | GTEX | — | 0.938 |
| 8 | SRR1485542 | GTEX | — | 0.936 |
| 9 | SRR607337 | GTEX | — | 0.936 |
| 10 | SRR1435484 | GTEX | — | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.427 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.343 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.235 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.231 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.203 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.199 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.199 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.157 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.126 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.114 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.085 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.059 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.039 | Inavolisib | — uncovered |